Dan Mitchell Included Into BOD Of ACRA Biopharma (NASDAQ:ABIO)


Dallas, Texas 02/13/2014 (FINANCIALSTRENDS) – In a recent development Dan Mitchell has been included into board of directors list of ACRA Biopharma (NASDAQ:ABIO). He has been assigned with the responsibility to serve for the audit and nominating as well as corporate governance committees of the board of directors. Mr. Mitchell formed a venture capital firm in 1997 by the name of Sequel Ventures Partners, L.L.C and also acted as its manager as well as founder. Before he founded Sequel Ventures Mr. Mitchell also founded another firm by the name of Capital Health Venture Partners in 1986.

He is an MBA from the University of California at Berkeley and has got years of vast work experience with him. His appointment is seen as a positive point and after his appointment the company released a press statement in which it was told that the company believes that his inclusion into the company should be seen as another step towards growth and prosperity. During the last trading session the shares closed at $1.79 and its 52 week high is $3.93 and its 52 week low is $1.13. if we talk about the current market capitalization of this company then it comes out to be $28.06 million.

An Overview of the Company

ACRA Biopharma (NASDAQ:ABIO) is basically a biopharmaceutical company that is responsible for the development of the genetically-targeted therapies for different types of cardiovascular diseases. One of the key products that are offered by the company is called as Gencaro which is basically bucindolol hydrochloride and is a pharmacologically beta blocker, investigational and mild vasodilator being developed mainly for atrial fibrillation.

The company has also identified some key and common genetic variations that can predict individual patient’s response to their key product that is Gencaro. The company has also done tie-up with Medtronic Inc. for conducting Genetic-AF trail.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.